Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8699340rdf:typepubmed:Citationlld:pubmed
pubmed-article:8699340lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:8699340lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:8699340lifeskim:mentionsumls-concept:C0021081lld:lifeskim
pubmed-article:8699340lifeskim:mentionsumls-concept:C0209368lld:lifeskim
pubmed-article:8699340pubmed:issue3lld:pubmed
pubmed-article:8699340pubmed:dateCreated1996-9-5lld:pubmed
pubmed-article:8699340pubmed:abstractTextMycophenolate mofetil (MPM), a new immunosuppressant, is the morpholinoethyl ester of mycophenolic acid (MPA). The distribution in blood and pharmacokinetics of MPA after administration of MPM were examined. The plasma to erythrocyte concentration ratio was low (0.10-0.15). MPA existed in rat plasma as the highly bound form (bound fraction was 9.79 +/- 0.57%). MPA disappeared from the systemic circulation with biexponential decay. After i.v. administration of MPM at the doses of 8.3, 16.7, and 33.3 mg/kg, the total clearance of MPA was 0.241 +/- 0.056, 0.321 +/- 0.126, and 0.317 +/- 0.092 L/h/kg, respectively. The terminal elimination half-live were 5.17 +/- 1.44, 8.89 +/- 2.76, and 7.94 +/- 2.94 h, respectively. After i.d. administration of MPM at the doses of 8.3, 16.7, 33.3, and 50.0 mg/kg, the terminal elimination half-live were 6.41 +/- 4.16, 4.49 +/- 2.20, 7.58 +/- 3.72, and 8.18 +/- 1.32 h, respectively. The mean peak times were within 30 min. The systemic availability of MPA after i.d. administration of MPM (at 8.3, 16.7, and 33.3 mg/kg) was calculated using the corresponding mean AUCiv, and the values were 84.3 +/- 35.0%, 69.9 +/- 25.7%, and 63.6 +/- 8.8%, respectively.lld:pubmed
pubmed-article:8699340pubmed:languageenglld:pubmed
pubmed-article:8699340pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8699340pubmed:citationSubsetIMlld:pubmed
pubmed-article:8699340pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8699340pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8699340pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8699340pubmed:statusMEDLINElld:pubmed
pubmed-article:8699340pubmed:monthMarlld:pubmed
pubmed-article:8699340pubmed:issn0022-3549lld:pubmed
pubmed-article:8699340pubmed:authorpubmed-author:OhtaTTlld:pubmed
pubmed-article:8699340pubmed:authorpubmed-author:TakadaKKlld:pubmed
pubmed-article:8699340pubmed:authorpubmed-author:KishimotoHHlld:pubmed
pubmed-article:8699340pubmed:authorpubmed-author:KoyamaHHlld:pubmed
pubmed-article:8699340pubmed:authorpubmed-author:YasumuraTTlld:pubmed
pubmed-article:8699340pubmed:authorpubmed-author:SugiokaNNlld:pubmed
pubmed-article:8699340pubmed:issnTypePrintlld:pubmed
pubmed-article:8699340pubmed:volume85lld:pubmed
pubmed-article:8699340pubmed:ownerNLMlld:pubmed
pubmed-article:8699340pubmed:authorsCompleteYlld:pubmed
pubmed-article:8699340pubmed:pagination335-8lld:pubmed
pubmed-article:8699340pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:8699340pubmed:meshHeadingpubmed-meshheading:8699340-...lld:pubmed
pubmed-article:8699340pubmed:meshHeadingpubmed-meshheading:8699340-...lld:pubmed
pubmed-article:8699340pubmed:meshHeadingpubmed-meshheading:8699340-...lld:pubmed
pubmed-article:8699340pubmed:meshHeadingpubmed-meshheading:8699340-...lld:pubmed
pubmed-article:8699340pubmed:meshHeadingpubmed-meshheading:8699340-...lld:pubmed
pubmed-article:8699340pubmed:meshHeadingpubmed-meshheading:8699340-...lld:pubmed
pubmed-article:8699340pubmed:meshHeadingpubmed-meshheading:8699340-...lld:pubmed
pubmed-article:8699340pubmed:year1996lld:pubmed
pubmed-article:8699340pubmed:articleTitlePharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats.lld:pubmed
pubmed-article:8699340pubmed:affiliationDepartment of Hospital Pharmacy, Kyoto Prefectural University of Medicine, Japan.lld:pubmed
pubmed-article:8699340pubmed:publicationTypeJournal Articlelld:pubmed